{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:23:21Z","timestamp":1788927801919,"version":"build-2803163510"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1097\/jcp.0b013e3181f14098","type":"journal-article","created":{"date-parts":[[2010,9,2]],"date-time":"2010-09-02T08:13:40Z","timestamp":1283415220000},"page":"531-540","source":"Crossref","is-referenced-by-count":74,"title":["Incidence of Extrapyramidal Symptoms and Tardive Dyskinesia in Schizophrenia"],"prefix":"10.1097","volume":"30","author":[{"given":"Diego","family":"Novick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep Maria","family":"Haro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Bertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210128","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-3-642-70140-5_10","article-title":"Involuntary disorders of movement in chronic schizophrenia-the role of the illness and its treatment.","volume":"2","author":"Owens","year":"1985","journal-title":"Psychopharmacology Suppl"},{"key":"R2-8-20210128","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00002018-200528030-00002","article-title":"Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management.","volume":"28","author":"Pierre","year":"2005","journal-title":"Drug Safety"},{"issue":"9657","key":"R3-8-20210128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"R4-8-20210128","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00023210-200721110-00004","article-title":"Adverse effects of atypical antipsychotics: differential risk and clinical implications.","volume":"21","author":"Haddad","year":"2007","journal-title":"CNS Drugs"},{"key":"R5-8-20210128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00131746-200701000-00003","article-title":"EPS profiles: the atypical antipsychotics are not all the same.","volume":"13","author":"Weiden","year":"2007","journal-title":"J Psychiatr Pract"},{"key":"R6-8-20210128","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/00004714-198706000-00008","article-title":"Anticholinergic prophylaxis of acute haloperidol-induced dystonic reactions.","volume":"7","author":"Boyer","year":"1987","journal-title":"J Clin Psychopharmacol"},{"key":"R7-8-20210128","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1001\/jama.1961.03040120016004","article-title":"A survey of drug-induced extrapyramidal reactions.","volume":"175","author":"Ayd","year":"1961","journal-title":"JAMA"},{"key":"R8-8-20210128","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/j.1440-1614.2000.00737.x","article-title":"The current status of tardive dyskinesia.","volume":"34","author":"Sachdev","year":"2000","journal-title":"Aust NZ J Psychiatry"},{"key":"R9-8-20210128","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/archpsyc.1980.01780250054006","article-title":"Changes in prevalence, severity and recovery in tardive dyskinesia with age.","volume":"37","author":"Smith","year":"1980","journal-title":"Arch Gen Psychiatry"},{"key":"R10-8-20210128","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second generation antipsychotics: a systematic review of 1-year studies.","volume":"161","author":"Correll","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R11-8-20210128","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.schres.2005.07.034","article-title":"Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial.","volume":"80","author":"Miller","year":"2005","journal-title":"Schizophr Res"},{"key":"R13-8-20210128","first-page":"254","article-title":"Integrating incidence and prevalence of tardive dyskinesia.","volume":"22","author":"Kane","year":"1986","journal-title":"Psychopharmacol Bull"},{"key":"R14-8-20210128","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/schbul\/18.4.701","article-title":"Gender differences in tardive dyskinesia: a critical review of the literature.","volume":"18","author":"Yassa","year":"1992","journal-title":"Schizophr Bull"},{"key":"R15-8-20210128","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.schres.2005.07.032","article-title":"Tardive dyskinesia: analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America.","volume":"81","author":"Kasper","year":"2006","journal-title":"Schizophr Res"},{"key":"R16-8-20210128","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/070674370505000907","article-title":"Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction.","volume":"50","author":"Margolese","year":"2005","journal-title":"Can J Psychiatry"},{"key":"R17-8-20210128","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1034\/j.1600-0447.2003.00064.x","article-title":"The European Schizophrenia Outpatient Health Outcome (SOHO) study: rationale, methods and recruitment.","volume":"107","author":"Haro","year":"2003","journal-title":"Acta Psychiatrica Scand"},{"key":"R19-8-20210128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.euroneuro.2006.09.005","article-title":"Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results.","volume":"17","author":"Haro","year":"2007","journal-title":"Eur Neuropsychopharmacol"},{"key":"R20-8-20210128","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00213-007-0730-2","article-title":"Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study.","volume":"191","author":"Novick","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"R21-8-20210128","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.schres.2008.11.007","article-title":"Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study.","volume":"108","author":"Novick","year":"2009","journal-title":"Schizophr Res"},{"key":"R22-8-20210128","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.euroneuro.2009.03.003","article-title":"Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.","volume":"19","author":"Novick","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"R23-8-20210128","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol: the current state of play.","volume":"37","year":"1996","journal-title":"Health Policy"},{"key":"R24-8-20210128","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00023210-200216010-00003","article-title":"Effects of newer antipsychotics on extrapyramidal function.","volume":"16","author":"Tarsy","year":"2002","journal-title":"CNS Drugs"},{"issue":"2","key":"R25-8-20210128","first-page":"CD005237","article-title":"Risperidone versus olanzapine for schizophrenia.","volume":"19","author":"Jayaram","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"R26-8-20210128","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/0269881108096070","article-title":"A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.","volume":"24","author":"Chan","year":"2010","journal-title":"J Psychopharmacol"},{"key":"R27-8-20210128","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine D(2) receptors explain the action of atypical antipsychotics? A new hypothesis.","volume":"158","author":"Kapur","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R28-8-20210128","first-page":"81","article-title":"Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia.","volume":"28","author":"Chakos","year":"1992","journal-title":"Psychopharmacol Bull"},{"key":"R29-8-20210128","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1176\/ajp.151.12.1819","article-title":"Predictors of acute dystonia in first-episode psychotic patients.","volume":"151","author":"Aguilar","year":"1994","journal-title":"Am J Psychiatry"},{"key":"R30-8-20210128","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1192\/bjp.174.1.23","article-title":"Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.","volume":"174","author":"Beasley","year":"1999","journal-title":"Br J Psychiatry"},{"key":"R31-8-20210128","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0278-5846(01)00303-7","article-title":"Improvement of tardive dyskinesia following switch from neuroleptics to olanzapine.","volume":"26","author":"Lykouras","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R32-8-20210128","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.pnpbp.2004.05.016","article-title":"Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods.","volume":"28","author":"Kinon","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R33-8-20210128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF01245320","article-title":"An experimental model of tardive dyskinesia.","volume":"33","author":"Klawans","year":"1972","journal-title":"J Neural Trans"},{"key":"R34-8-20210128","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/309347a0","article-title":"Association with persistent neuroleptic-induced dyskinesia of regional changes in brain: GABA synthesis.","volume":"309","author":"Gunne","year":"1984","journal-title":"Nature"},{"key":"R35-8-20210128","first-page":"191","article-title":"Pathophysiology of tardive dyskinesia.","volume":"232","author":"Gunne","year":"1985","journal-title":"Psychopharmacology"},{"key":"R36-8-20210128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF00429003","article-title":"Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients.","volume":"81","author":"Csernansky","year":"1983","journal-title":"Psychopharmacology (Berl)"},{"key":"R37-8-20210128","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00004850-198604000-00005","article-title":"The prevalence of abnormal involuntary movements among chronic schizophrenics.","volume":"1","author":"Guy","year":"1986","journal-title":"Int Clin Psychopharmacol"},{"key":"R38-8-20210128","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug induced akathisia.","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"R39-8-20210128","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00005053-198406000-00002","article-title":"Positive and negative syndromes in chronic schizophrenic inpatients.","volume":"172","author":"Opler","year":"1984","journal-title":"J Nerv Ment Dis"},{"key":"R40-8-20210128","first-page":"130","article-title":"Tardive dyskinesia and depressive symptoms in schizophrenics.","volume":"21","author":"Richardson","year":"1985","journal-title":"Psychopharmacol Bull"},{"key":"R41-8-20210128","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.comppsych.2007.05.003","article-title":"Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study.","volume":"48","author":"Tenback","year":"2007","journal-title":"Compr Psychiatry"},{"key":"R42-8-20210128","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/sj.npp.1301044","article-title":"Tardive dyskinesia in schizophrenia is associated with prolactin-related sexual disturbances.","volume":"31","author":"Tenback","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"R43-8-20210128","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1176\/ajp.138.3.297","article-title":"Changing epidemiology of tardive dyskinesia: an overview.","volume":"138","author":"Jeste","year":"1981","journal-title":"Am J Psychiatry"},{"key":"R44-8-20210128","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archpsyc.1982.04290040069010","article-title":"Tardive dyskinesia: prevalence and risk factors, 1959-1979.","volume":"39","author":"Kane","year":"1982","journal-title":"Arch Gen Psychiatry"},{"key":"R45-8-20210128","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/archpsyc.1986.01800020101018","article-title":"Duration of treatment relationships for involuntary movements (tardive dyskinesia): concordance between cross-sectional, clinical and longitudinal animal studies.","volume":"43","author":"Waddington","year":"1986","journal-title":"Arch Gen Psychiatry"},{"key":"R46-8-20210128","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1192\/bjp.149.5.616","article-title":"Late onset involuntary movements in chronic schizophrenia: relationship of tardive dyskinesia to intellectual impairment and negative symptoms.","volume":"149","author":"Waddington","year":"1986","journal-title":"Br J Psychiatry"},{"key":"R47-8-20210128","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1176\/ajp.143.9.1162","article-title":"An unusual cluster of tardive dyskinesia in schizophrenia: association with cognitive dysfunction and negative symptoms.","volume":"143","author":"Waddington","year":"1986","journal-title":"Am J Psychiatry"},{"key":"R48-8-20210128","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.1991.03470170090030","article-title":"Prospective study of tardive dyskinesia incidence in the elderly.","volume":"266","author":"Saltz","year":"1991","journal-title":"JAMA"},{"key":"R50-8-20210128","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1176\/ajp.156.2.309","article-title":"Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients.","volume":"156","author":"Jeste","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R52-8-20210128","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/archpsyc.1993.01820210057007","article-title":"Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptics. Results of the Yale Tardive Dyskinesia Study.","volume":"50","author":"Morgenstern","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"R53-8-20210128","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1176\/ajp.129.4.466","article-title":"Prevention and management of tardive dyskinesia.","volume":"129","author":"Crane","year":"1972","journal-title":"Am J Psychiatry"},{"key":"R54-8-20210128","first-page":"259","article-title":"A five year follow-up study of tardive dyskinesia.","volume":"22","author":"Chouinard","year":"1986","journal-title":"Psychopharmacol Bull"},{"key":"R55-8-20210128","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/archpsyc.1995.03950210050010","article-title":"Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.","volume":"52","author":"Jeste","year":"1995","journal-title":"Arch Gen Psychiatry"},{"key":"R56-8-20210128","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1176\/ajp.155.11.1521","article-title":"Prospective study of tardive dyskinesia in the elderly: rates and risk factors.","volume":"155","author":"Woerner","year":"1998","journal-title":"Am J Psychiatry"},{"key":"R57-8-20210128","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/j.1440-1614.2004.01382.x","article-title":"Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study.","volume":"38","author":"Sachdev","year":"2004","journal-title":"Aust N Z J Psychiatry"},{"key":"R58-8-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects.","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"suppl 416","key":"R59-8-20210128","first-page":"1","article-title":"The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment.","volume":"107","author":"Haro","year":"2003","journal-title":"Acta Psychiatr Scand"},{"key":"R60-8-20210128","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJMoa002028","article-title":"A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.","volume":"346","author":"Csernansky","year":"2002","journal-title":"N Engl J Med"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004714-201010000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:37:13Z","timestamp":1786041433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-201010000-00008"}},"subtitle":["Thirty-Six-Month Results From the European Schizophrenia Outpatient Health Outcomes Study"],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3181f14098","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}